TNFRSF17 and neoplasm: Chimeric antigen receptor (CAR) T-cells targeting BCMA are one type of immunotherapies that can induce both tumor-directed cytotoxicity and immunological memory; they have demonstrated unequivocal efficacy in RRMM.